Fig. 7
SOX10 depletion sensitizes melanoma cells to mutant BRAF inhibitor. a Melanoma cells were transfected with control or SOX10 #2 siRNAs for 72 h and ±2 μM vemurafenib for additional 24 h. Cells were then stimulated with 10 ng ml–1 NRG1 for 1 h and lysed for western blot analysis. b Melanoma cells were transfected with Control, SOX10#1 or #2 siRNAs for 48 h and treated with ±10 μM Vemurafenib for additional 48 (1205Lu) or 72 (A375) hours. Cells were then collected and stained with Annexin-V/PI for flow cytometry analysis. Average percent of annexin-V positive cells from three independent experiments are shown. Error bars represent standard deviation. Significance was determined by ANOVA one-way test, ***p < 0.001. c Growth curves of tumors formed by 1205Lu-TR or A375-TR cells harboring control or SOX10-shRNAs in nude mice (N = 7 per condition). Statistical analyses (ANOVA test) were performed on tumor volume differences between RAFi-treated control-shRNA group and RAFi-treated SOX10-shRNA groups on day 12 (A375) or 14 (1205Lu). Error bars represent standard error. Significance was determined by ANOVA one-way test, *p < 0.05. d Western blot analysis of two sets of representative tumor samples excised on day 5. Uncropped images are shown in Supplementary Fig. 15
